Learn More ResMed Inc (ASX: RMD) shares are in the red so far in 2025. After slipping from 52-week highs of $40.50 in January, shares in the respiratory device company currently fetch $35.71 apiece.
But, new evidence strongly supports the use of NIV for patients with advanced COPD and persistent hypercapnia. The study 2, supported by funding and products by Philips Respironics and ResMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback